

## Buscopan (Hyoscine) Pre-administration Checklist:

### Presence of any following:

Cardiac risk factors (relative contraindication)	Tick if present
Uncontrolled heart failure	
Tachyarrhythmia	
Recent myocardial infarct or unstable angina	
Significant risk of urinary retention (such as BPH)	
Prior allergic reaction to Buscopan	

Absolute contraindications:	Tick if present
Repeated vomiting or no bowel opening for 3 more days (screening for paralytic ileus, mechanical obstruction, toxic megacolon)	
Myasthenia Gravis	
History of narrow angle glaucoma	

If no contraindications are present: proceed with examination.

If any absolute or relative contraindications identified, do NOT administer Buscopan. Inform the radiologist in charge of study for further consideration:

For patients with any contraindications with good benefit/risk opting to proceed with Buscopan administration, the Radiologists should ensure that:

1. Patient is fully informed of risk/benefit. Ensure written consent signed include risks of Buscopan administration.
2. Obtain BP/P readings before Buscopan administration are acceptable.
3. BP/P performed immediately after Buscopan administration. Cardiac monitoring during the study and BP/P immediately after the examination.
4. Ensure absence of significant cardiac symptoms (chest pain, palpitation) before discharge.

**RIS template documentation:**

Option 1: Clear documentation of Buscopan administration in presence of Cardiac or other relative contraindication after benefit/risks weighed.

Relative contraindication of \_\_\_\_\_ identified in pre-administration checklist. Opted to administer Buscopan after consideration of risk-benefit for this patient. Buscopan 20mg IV injection performed. Hemodynamic status during and after the procedure was unremarkable. No adverse effects encountered.

Option 2: Withholding of Buscopan due to significant contraindication +/- Glucagon administration

In view of the contraindication for Buscopan administration (insert contraindication), Buscopan was not administered after careful consideration of risk/benefit ratio.

Opted for Glucagon 1mg IVI as alternate agent to facilitate bowel relaxation after exclusion of major contraindications (pheochromocytoma, insulinoma, glucagonoma).

Option 3: Generic template documenting exclusion of contraindications in a patient without ANY contraindications.

Buscopan 20mg IVI was administered after exclusion of major contraindications. No adverse effects encountered.

Reference:

<https://www.mims.com/hongkong/drug/info/buscopan?type=full>

<https://www.mims.com/hongkong/drug/info/glucagon?mtime=generic>